预约演示
Research Conducted by Florida Cancer Specialists & Research InstituteCancer Specialists & Research Institute Featured at European Society of Medical Oncology 2023 Congress
2023-10-20
临床1期ASCO会议临床3期临床2期免疫疗法
Global gathering highlights cutting-edge developments in cancer care
FORT MYERS, Fla., Oct. 20, 2023 /PRNewswire/ -- Research conducted by Florida Cancer Specialists & Research Institute, LLCCancer Specialists & Research Institute, LLC (FCS) is featured this week among the latest advancements and findings in cancer care at the European Society of Medical Oncology (ESMO) Congress in Madrid, Spain. Five FCS physicians are the first authors and/or co-authors of 12 cancer research studies that will be shared at the global gathering of oncologists, researchers, patient advocates, pharmaceutical representatives and journalists. With more than 30,000 members from 168 countries worldwide, ESMO is the leading professional organization for medical oncology.
Continue Reading
Several researchers from Florida Cancer Specialists & Research Institute will present their findings on groundbreaking clinical trials at the 2023 European Society of Medical Oncology (ESMO) Congress in Madrid, Spain.
The following FCS physiciFlorida Cancer Specialists & Research InstituteCancerrs will present research results during oral presentations, poster discussions and/or proffered paper sessions:
Manish R. Patel, MD, FCS director of drug development, as first author of a Phase 1/2 study of Ifinatamab deruxtecan in patients with advanced solid tumors; a Phase I trial of the ATR inhibitor, ART0380, in advanced solid tumors; a Phase I dose-escalation and expansion study evaluating the safety and efficacy of brigimadlin in patients with solid tumors; as senior author of a Phase 1 trial of an anti-SIRPa monoclonal antibody in patients with advanced solid tumors; Updated results from the phase I/II study of OP-1250, an oral complete estrogen receptor (ER) antagonist (CERAN) and selective ER degrader (SERD) in patients (pts) with advanced or metastatic ER-positive, HER2-negative breast cancer
Ivor Percent, MD, a Phase 3 study of Sitravatinib plus Nivolumab versus Docetaxel in patients wIfinatamab deruxtecand advanced non-squadvanced solid tumorslung cancer (proffered paATR inhibitorATR session)ART0380advanced solid tumorsbrigimadlinsolid tumorsanti-SIRPa monoclonal antibody
Cesar Perez, MD, an oral presentationSitravatinibant prNivolumab resultsDocetaxelst-in-human Phase 1 study of SGN-B7H4advanced non-squamous non-small cell lung cancerate in patients with advanced solid tumors; and poster discussions/presentations as co-author of a Phase 1, first-in-human study of the pan-RAF inhibitor JZP815 for advanced or metastatic solid tumors; a first-in-human study of a the folate receptor Conjugate ELU001 for patients with solid tumors; a Phase 1 trial of an ATR inhibitor in advanced solid tumors; and a Phase 2 Trial of a selective gamma secretase inhibitor in patients with recurring/metastatic (R/M) adenoid cystic carcinoma
Alexander Philipovskiy, MD, PhD,, an oral presentation as co-author of a first-in-human Phase 1 study of RaludSGN-B7H4VruxtB7-H4monotherapy in patients with previously treated ovarian canadvanced solid tumorspan-RAF inhibitorJZP815advanced or metastatic solid tumorsfolate receptorELU001solid tumors
James Reeves, MD (retired), ctDNA Reduction and Clinical Efficacy of the Darovasertib + Crizotinib CombinRaludotatugtderuxtecanlanomaovarian cancer
Judy Wang, MD, FCS associate director of drug development, co-author of aDarovasertibentCrizotinibhase 1, open-labmetastatic melanoma(FIH) study of JZP815 in advanced or metastatic solid tumors harboring mitogen-activated protein kinase (MAPK) alterations
FCS President and Managing Physician Lucio N. Gordan, MD said, "With one of the largest clinical research programs in the U.S., FCS is proud to be oJZP815foreadvanced or metastatic solid tumorsthat are prmitogen-activated protein kinase (MAPK)und the globe."
"The ESMO Congress is a highly influential platform and we are delighted to join with colleagues and peers to share exciting discoveries in cancer prevention, diagnosis, treatment and survivorship," said Manish Patel, MD.cancer
The ESMO Congress 2023 is a global stage for the exchange of potentially practice-changing data and multidisciplinary conversations that wilcancer transformative therapies against cancer. All of the study abstracts will be published online in the ESMO Congress 2023 Abstract Book, a supplement to the official ESMO journal, Annals of Oncology.
About Florida Cancer Specialists & Research Institute, LLC: (FLCancer.com)cancer
FloridFlorida Cancer Specialists & Research Institute, LLCCanceralists & Research Institute (FCS) offers patients access to more clinical trials than any private oncology practice in Florida. The majority of new cancer drugs recently approved for use in the U.S. were studied in clinical trials with FCS participation.* Recognized for our research, FCS is a recipient of the national Clinical Trials Participation Award presented by the American Society of Clinical Oncology (ASCO). FCS physicians, trained in prestigious medical schools and research institutes, are consistently ranked nationally as Top Doctors by U.S. News & World Report.
Florida Cancer Specialists & Research Institute (FCS)Cancer4, FCS has built a national reputation for excellence that is reflected in exceptional and compassionate patient care, driven by innovative clinical reseacancerutting-edge technologies and advanced treatments, including targeted therapies genomic-based treatment and immunotherapy. Our highest values are embodied by our outstanding team of highly trained and dedicated physicians, clinicians and staff.
*Prior to approval
SOURCE Florida Cancer Specialists & Research Institute
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。